{"disease":{"id":"severe-pain","name":"Severe pain","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":23,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"buprenorphine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"naloxone","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Narcan","generic_name":"NALOXONE","company_name":"Adapt","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"methadone","indication_name":"Severe and Persistent Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadone Hydrochloride","generic_name":"METHADONE","company_name":"Specgx Llc","drug_phase":"marketed","molecular_target":"mu-opioid receptors, NMDA receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Methadone is a synthetic opioid that acts as a mu-agonist, providing analgesia and aiding in opioid addiction management."},{"drug_id":"levorphanol","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levo-Dromoran","generic_name":"LEVORPHANOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":64,"revenue":null,"mechanism":"Levorphanol binds primarily to mu-opioid receptors to produce analgesia, with no ceiling effect for pain relief."},{"drug_id":"pentazocine","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENTAZOCINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"nalbuphine-hydrochloride","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NALBUPHINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"kappa opioid receptors, mu opioid receptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Nalbuphine activates kappa opioid receptors and blocks mu opioid receptors."},{"drug_id":"pentazocine-hydrochloride","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENTAZOCINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1718","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NALOXONE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"ziconotide-acetate","indication_name":"Severe Chronic Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ZICONOTIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":32,"revenue":null,"mechanism":null},{"drug_id":"butorphanol-tartrate","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUTORPHANOL TARTRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"diamorphine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heroin","generic_name":"diamorphine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"Opioid Agonist","quality_score":null,"revenue":null,"mechanism":"Heroin works by binding to opioid receptors in the brain, mimicking the action of natural pain-relieving chemicals."},{"drug_id":"clonidine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Catapres-Tts-1","generic_name":"CLONIDINE","company_name":"Lavipharm","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"hydromorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"hydromorphone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"oliceridine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olinvyk","generic_name":"OLICERIDINE","company_name":"Trevena","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Olinvyk works by binding to the mu-type opioid receptor in the brain, which helps to reduce the perception of pain."},{"drug_id":"suzetrigine","indication_name":"moderate to severe acute pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Journavx","generic_name":"SUZETRIGINE","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Sodium Channel Blocker [EPC]","quality_score":65,"revenue":null,"mechanism":"Journavx blocks sodium channels in the nervous system to reduce pain signal transmission."},{"drug_id":"oxycodone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pethidine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pethidine","company_name":"","drug_phase":"unknown","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"clonidin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clonidin","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methadone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadone Hydrochloride","generic_name":"METHADONE","company_name":"Specgx Llc","drug_phase":"marketed","molecular_target":"mu-opioid receptors, NMDA receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Methadone is a synthetic opioid that acts as a mu-agonist, providing analgesia and aiding in opioid addiction management."},{"drug_id":"dextromoramide","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Moramide","generic_name":"DEXTROMORAMIDE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"dextromoramide","quality_score":0,"revenue":null,"mechanism":"Dextromoramide works by binding to opioid receptors in the brain, spinal cord, and other areas to produce analgesia and euphoria."},{"drug_id":"pethidin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pethidin","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"heroin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Heroin","company_name":"MetroHealth Medical Center","drug_phase":"phase_3","molecular_target":"D(1A) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"morphine","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"ibuprofen","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advil","generic_name":"ibuprofen","company_name":"Generic (originally Boots Group)","drug_phase":"marketed","molecular_target":"Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":40,"revenue":null,"mechanism":"Ibuprofen inhibits prostaglandin synthetase, reducing pain, fever, and inflammation."},{"drug_id":"demerol","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meperidine Hydrochloride Preservative Free","generic_name":"Meperidine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":72,"revenue":null,"mechanism":"Meperidine Hydrochloride Preservative Free works by binding to opioid receptors in the brain, altering the perception of and response to pain."},{"drug_id":"ketorolac","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toradol","generic_name":"KETOROLAC","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"Cyclooxygenase Inhibitor","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"morphine-sulfate","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"oxymorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxycontin","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"hydromorphone","indication_name":"Severe Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"methadon","indication_name":"Severe pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methadon","company_name":"University of Utah","drug_phase":"discontinued","molecular_target":"Neuronal acetylcholine receptor subunit alpha-10, D(4) dopamine receptor, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"dihydrocodeine","indication_name":"Moderate to moderately severe pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synalgos-Dc","generic_name":"DIHYDROCODEINE","company_name":"Caraco","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":54,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":39,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07344350","title":"A Non-randomised, Non-inferiority Comparative Study of Oral Actiskenan (Morphine Sulfate) Versus Intranasal Sufentanil in the Early Management of Severe Acute Pain in Emergency Departments.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Groupe Hospitalier de la Region de Mulhouse et Sud Alsace","has_results":false},{"nct_id":"NCT03618082","title":"GOAL-Directed ANalgesia (GOALDAN)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":380,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT02662764","title":"Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Talphera, Inc","has_results":true},{"nct_id":"NCT02603705","title":"Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":281,"lead_sponsor_name":"Egalet Ltd","has_results":false},{"nct_id":"NCT06237231","title":"Efficacy and Safety of DIT112 in the Treatment of Moderate to Severe Pain After Dental Surgery for the Extraction of Impacted Third Molars","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":252,"lead_sponsor_name":"EMS","has_results":false},{"nct_id":"NCT06904248","title":"Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Yangtze River Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT02095366","title":"Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT04812860","title":"A Study to Evaluate the Efficacy and Safety of HR18042 Tablets in the Treatment of Postoperative Pain of Impacted Tooth.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06995352","title":"Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":140,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT06091020","title":"A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Merz Therapeutics GmbH","has_results":false},{"nct_id":"NCT05096494","title":"Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Scilex Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05238571","title":"Does Re-surgery Improve Somatosensory Outcomes in Persistent Pain After Groin Hernia Repair","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"mads u werner","has_results":false},{"nct_id":"NCT03814993","title":"taPentadol cLinical prAcTice IN belgiUM","phase":"","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Dafne Balemans","has_results":false},{"nct_id":"NCT03942848","title":"Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02221674","title":"Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Grünenthal GmbH","has_results":true},{"nct_id":"NCT02680847","title":"Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04259723","title":"Virtual Reality Assisted Conscious Sedation During TAVI","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Klinik für Kardiologie, Pneumologie und Angiologie","has_results":false},{"nct_id":"NCT07189962","title":"A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT02101554","title":"Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03111277","title":"MR Guided Focused Ultrasound for Treatment of Neuropathic Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT03802227","title":"A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Nektar Therapeutics","has_results":true}],"total":21},"guidelines":[{"drug_id":"demerol","guideline_body":"FDA label","recommendation":"Meperidine Hydrochloride Tablets and Oral Solution are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.","line_of_therapy":"any","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}